Grants and Contributions:
Title:
RTC-PG Sustained Release Prostaglandins
Agreement Number:
1018655
Agreement Value:
$300,000.00
Agreement Date:
Apr 1, 2024 - Jan 31, 2025
Description:
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The Ripple pipeline currently has a variety of conjugates under development targeting key ocular indications such as glaucoma, DME and GA-AMD. Scientific and engineering resources will perform work on the manufacturability of Ripple’s prostaglandin conjugates (RTC-PGs) for the treatment of Primary Open Angle Glaucoma. The project will require analysis of data generated from chemistry, manufacturing and controls (CMC) development to develop the manufacturing know-how for a robust and sustainable licensing and commercialization process that can be applied to all pipeline products.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 1L7
Reference Number:
172-2024-2025-Q1-1018655
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
760459073
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 50,000 dollars.
Amendment Date
Jan 15, 2025
Recipient's Operating Name:
Ripple Therapeutics
Recipient's Legal Name:
Ripple Therapeutics Corporation
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
32541
Amendments: